RT Journal Article
SR Electronic
T1 Transcriptomics of Type 2 Diabetic and Healthy Human Neutrophils
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 19011353
DO 10.1101/19011353
A1 Kleinstein, Sarah E.
A1 McCorrison, Jamison
A1 Ahmed, Alaa
A1 Hasturk, Hatice
A1 Van Dyke, Thomas E.
A1 Freire, Marcelo
YR 2019
UL http://medrxiv.org/content/early/2019/11/08/19011353.abstract
AB Objectives Chronic inflammatory diseases, including diabetes and cardiovascular disease, are heterogeneous and often co-morbid, with increasing global prevalence. Uncontrolled type 2 diabetes (T2D) can result in severe inflammatory complications. As neutrophils are essential to inflammation, we conducted RNA-seq transcriptomic analyses to investigate the association between neutrophil gene expression and T2D phenotype. Further, as specialized pro-resolving lipid mediators, including resolvin E1 (RvE1), can actively resolve inflammation, we further surveyed the impact of RvE1 on isolated neutrophils.Methods Cell isolation and RNA-seq analysis of neutrophils from N=11 T2D and N=7 healthy individuals with available clinical data was conducted. Additionally, cultured neutrophils (N=3 T2D, N=3 healthy) were perturbed with increasing RvE1 doses (0nM, 1nM, 10nM, or 100nM) prior to RNA-seq. Data was evaluated through a bioinformatics pipeline including pathway analysis and post hoc false-discovery rate (FDR)-correction.Results We observed significant differential expression of 50 genes between T2D and healthy neutrophils (p<0.05), including decreased T2D gene expression in inflammatory- and lipid-related genes SLC9A4, NECTIN2 and PLPP3 (p<0.003). RvE1 treatment induced dose-dependent differential gene expression (uncorrected p<0.05) across groups, including 59 healthy and 216 T2D neutrophil genes. Comparing T2D to healthy neutrophils, 1097 genes were differentially expressed across RvE1 doses, including two significant genes, LILRB5 and AKR1C1, involved in inflammation (p<0.05).Conclusions Inflammatory- and lipid-related genes were differentially expressed between T2D and healthy neutrophils, and RvE1 dose-dependently modified gene expression in both groups. Unraveling the mechanisms regulating abnormalities in diabetic neutrophil responses could lead to better diagnostics and therapeutics targeting inflammation and inflammation resolution.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by U.S. Public Health Service Grants R00 DE0234804 (Freire), R01 DE025020 (Van Dyke), and K23 DE18917 (Hasturk) from the National Institutes of Health/National Institute of Dental and Craniofacial Research.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data is available in the manuscript and supplemental material. RNA-sequencing data will be deposited in an approved database.BMIBody-mass indexCPMCount per millionE-selectinEndothelial-selectinFDRFalse-discovery rateGOGene OntologyGWASGenome-wide association studiesHbA1cHemoglobin A1CIL-1RIL-1 receptorIP-10Interferon gamma-induced protein 10KEGGKyoto Encyclopedia of Genes and GenomesLLOQLower limit of quantificationP-SelectinPlatelet-selectinQCQuality controlRNA-seqRNA sequencingRvE1Resolvin E1sICAM-1Soluble intercellular adhesion molecule-1ST2Suppression of tumorigenicity 2T2DType 2 diabetesTMMTrimmed mean of M-values